The Evolving Management of Hepatitis C Virus

Hepatitis C virus (HCV) is the leading bloodborne chronic infection in the United States, with 3.2 million individuals believed to be infected. Injectable alpha interferons have historically been a mainstay of HCV therapy; however, they are only moderately effective and are challenging in terms of tolerability. Recent advances have led to the availability of interferon-free, all-oral, direct-acting antiviral medications that have made HCV therapy more efficacious and have simplified treatment regimens. These treatment regimens remain complicated, however, and guideline-based recommendations are continuing to evolve rapidly. The pharmacist should consult consensus HCV guidelines frequently in order to keep abreast of the most current recommendations for managing this patient population.